Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 139, 11-23
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences (UL1 TR00038)
- National Institutes of Health
- Laura and Isaac Perlmutter Cancer Center (NIH/NCI P30CA016087)
- National Institutes of Health S10 (NIH/ORIP S10OD01058, S10OD018338)
- Reata Pharmaceuticals
This publication has 25 references indexed in Scilit:
- Toward clinical application of the Keap1–Nrf2 pathwayTrends in Pharmacological Sciences, 2013
- New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative StressJournal of Natural Products, 2011
- Decreasing Intracellular Superoxide Corrects Defective Ischemia-induced New Vessel Formation in Diabetic MiceJournal of Biological Chemistry, 2008
- db/db mice exhibit severe wound‐healing impairments compared with other murine diabetic strains in a silicone‐splinted excisional wound modelWound Repair and Regeneration, 2007
- Risk Factors for Recurrent Diabetic Foot UlcersDiabetes Care, 2007
- Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genesMolecular Cancer Therapeutics, 2007
- The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE SignalingCancer Research, 2005
- Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow–derived cellsBlood, 2005
- Quantitative and reproducible murine model of excisional wound healingWound Repair and Regeneration, 2004
- Topical Vascular Endothelial Growth Factor Accelerates Diabetic Wound Healing through Increased Angiogenesis and by Mobilizing and Recruiting Bone Marrow-Derived CellsThe American Journal of Pathology, 2004